Bruce G. Pollock

Dr. Bruce Pollock teaches and conducts research in geriatric clinical psychopharmacology with over 300 peer reviewed publications and is listed by ISI as among the 1% most cited authors in the field of geriatric psychiatry.

Dr. Pollock received his PhD in Pharmacology from the University of Pittsburgh. His work includes: 1) clinical studies examining neurochemical selectivity, pharmacokinetics, and neurophysiological-therapeutic effects of conventional or newly derived/modified agents for the treatment of depression and the behavioral disturbances of dementia, and 2) examination of age-related changes in drug metabolism and pharmacodynamics toward optimizing treatment with antidepressants and antipsychotics. He has had a leadership role in numerous clinical trials and the U.S. National Institutes of Health has continuously funded his research since 1990.

Dr. Pollock is a Distinguished Life Fellow of the American Psychiatric Association (APA), a  Distinguished Fellow of the Canadian Psychiatric Association (CPA), has been honored with the Distinguished Investigator Award of the American Association for Geriatric Psychiatry (AAGP), and served as President of the AAGP - the first Canadian to serve in this position. He has also been awarded the Jack Weinberg Memorial Award for excellence in Geriatric Psychiatry from the APA, the Award for Research in Geriatric Psychiatry by the American College of Psychiatrists, and was the recipient of the 2014 William B. Abrams Award in Geriatric Clinical Pharmacology from the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

Selected Publications

1. Roostaei T, Nazeri A, Felsky D, De Jager PL, Schneider JA, Pollock BG, Bennett DA, Voineskos AN for the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. Mol Psyc: 2(2):287-295, 2017 (Feb)
2. Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC, Graff-Guerrero A: Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. Am J Geriatr Psychiatry: 25(1): 1-10, 2017 (Jan)
3. Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, Porsteinsson AP, Schneide LS,  Weintraub D, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos CG, Bies RR:  R-and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.   Br J Clin Pharmacol: 82(3):784-92, 2016 (Sept)
4. Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG for for the CitAD Research Group: A Population Pharmacokinetic Model for R- and S- Citalopram and Desmethylcitalopram in Alzheimer's Disease Patients with Agitation. J Pharmacokinet and Pharmacodyn:  43(1):99-109, 2016 (Feb)
5. Suridjan I, Pollock BG, Verhoeff NP, Voineskos AN, Chow T, Rusjan PM, Lobaugh NJ, Houle S, Mulsant BH, Mizrahi R: In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a Positron emission tomography study with a novel radioligand, [18F]-FEPPA. Molecular Psychiatry: 20(12):1579-87, 2015 (Dec)
6. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C,  Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG for the CitAD Research Group: Effect of Citalopram on Agitation in Alzheimer's Disease: The CitAD Randomized Controlled Trial. JAMA: 311:682-691, 2014 (Feb)
7. Chow TW, Fam D, Graff-Guerrero A, Verhoeff NPG, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG: Fluodeoxyglucose positron emission tomography (FDG-PET) in semantic dementia after 6 months of memantine: An open-label pilot study. Int J Geriatr Psychiatry: 28:319-25, 2013 (Mar)
8. Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR, for the DIADS-2 Research Group: Population pharmacokinetic modeling of sertraline treatment in Alzheimer’s Disease patients: The DIADS-2 study. J Clin Pharmacol: 53:234-9, 2013 (Feb)
9. Wojtalik JA, Eack SM, Pollock BG, Keshavan MS: Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. Psychiatry Research: 204:61-7, 2012 (Nov)
10. Wessels AM, Jin Y, Pollock BG, Lange AC, Vrijens B, Fagiolini A, Kupfer D, Rucci P, Kepple G, Anderton J, Buttenfield J, Bies RR, Frank E: Adherence to Escitalopram Treatment in Depression: A study of electronically compiled dosing histories in the “Depression, The Search for Phenotypes” study. Int Clin Psychopharmacol: 27:291-7, 2012 (Nov)
11. Sherer EA, Sale M, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR: Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic building. Journal of Pharmacokinetics and Pharmacodynamics: 39:393-414, 2012 (Aug)
12. Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA: The greater sensitivity of elderly APOE є4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. The American Journal of Geriatric Pharmacotherapy 10: 185-192, 2012 (Jun)